The Corporate Liaison Board of the Endocrine Society

Corporate Liaison Board Mission Statement

The Corporate Liaison Board (CLB) supports the Endocrine Society mission of advancing patient care by:

  • Promoting reciprocal partnerships with the business, medical, and scientific leadership of the respective organizations;
  • Advising of industry trends and needs with strategic objectives of the Society and the Hormone Health Network;
  • Fostering partnerships and collaborations between the Society, the Hormone Health Network, and industry involving projects and services of common interest;
  • Recognizing the scientific and professional contributions of Society members who work in industry;
  • Educating industry colleagues with an interest in endocrinology about the benefit of Society interactions;
  • Encouraging the presentation of industry science at appropriate venues and submission of endocrine manuscripts to Society journals;
  • Identifying industry career paths for trainees.

Revised by Corporate Liaison Board on March 7, 2014.

Learn more about the goals of the Corporate Liaison Board.

Corporate Liaison Board Members

  • Abbott Diabetes Care Inc.
  • AbbVie Inc.
  • Akcea Therapeutics
  • Amgen Inc.
  • Ascendis Pharma Inc.
  • AstraZeneca
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Dexcom, Inc.
  • Eisai Inc.
  • Insulet Corporation
  • Janssen Pharmaceuticals, Inc.
  • Lilly USA, LLC
  • Medtronic Diabetes
  • Merck & Co., Inc.
  • Merck-Pfizer Diabetes Collaboration
  • Novo Nordisk Inc.
  • Pfizer, Inc.
  • Roche – Diabetes Care
  • sanofi
  • Shire International GmbH
  • Therapeutics MD, Inc.